Intervention Review

Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants

  1. Keith J Barrington1,*,
  2. Luc P Brion2

Editorial Group: Cochrane Neonatal Group

Published Online: 22 JUL 2002

Assessed as up-to-date: 3 AUG 2009

DOI: 10.1002/14651858.CD003213

How to Cite

Barrington KJ, Brion LP. Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003213. DOI: 10.1002/14651858.CD003213.

Author Information

  1. 1

    CHU Ste-Justine, Department of Pediatrics, Montreal, Quebec, Canada

  2. 2

    University of Texas Southwestern at Dallas, Division of Neonatal-Perinatal Medicine, Dallas, Texas, USA

*Keith J Barrington, Department of Pediatrics, CHU Ste-Justine, 3175 Cote Ste Catherine, Montreal, Quebec, H3T 1C5, Canada.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 22 JUL 2002




  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要


Indomethacin therapy for closure of patent ductus arteriosus (PDA) frequently causes oliguria and occasionally more serious renal dysfunction. Low dose dopamine has been suggested as a means for preventing this side effect.


To determine whether dopamine therapy prevents indomethacin-mediated deterioration in renal function in the preterm newborn infant without serious adverse effects. Subgroup analyses were planned to assess the effects of dopamine on patients given indomethacin as prophylaxis of intraventricular hemorrhage, and patients given indomethacin as treatment of PDA.

Search methods

Standard methods of the Cochrane Neonatal Review Group (CNRG) were used. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3, 2009), MEDLINE (1966 to 2009), EMBASE (1974 to 2009) and CINAHL (2001 to 2009). In addition, we contacted the principal investigators if necessary to ascertain required information.

Selection criteria

Randomized or quasi-randomized studies of the effects of dopamine on urine output, glomerular filtration rate, fluid balance or incidence of renal failure, in preterm newborn infants receiving indomethacin. The comparison group should have received no dopamine.

Data collection and analysis

We used the standard methods of the Cochrane Collaboration and those of the CNRG. For categorical outcomes, we calculated typical estimates for relative risk and risk difference. For continuous outcomes the weighted mean difference (WMD) was calculated. Fixed effect models were assumed for meta-analysis.

Main results

Three studies were found (total number randomized patients 75) that fulfilled the entry criteria for this review. All were single center trials that enrolled NICU patients receiving indomethacin for symptomatic PDA. There are no (or only partial) results for effects of dopamine on several of the primary outcomes, including death before discharge, serious intraventricular hemorrhage, cystic periventricular leukomalacia, or renal failure. There has been inadequate investigation of the effects of dopamine on cerebral perfusion or cardiac output, or GI complications, or endocrine toxicity. Dopamine improved urine output [WMD 0.68 ml/kg/hour (95% CI 0.22, 1.44)], but there was no evidence of effect on serum creatinine (WMD 2.04 micromoles/liter, CI -17.90, 21.97) or the incidence of oliguria (urine output < 1 ml/kg/hour) (RR 0.73, CI 0.35, 1.54). There was no evidence of effect of dopamine on the frequency of failure to close the ductus arteriosus (RR 1.11, CI 0.56, 2.19).

Authors' conclusions

There is no evidence from randomized trials to support the use of dopamine to prevent renal dysfunction in indomethacin-treated preterm infants.


Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants

Dopamine has not been shown to prevent adverse effects of indomethacin on the kidneys of preterm babies. Indomethacin is a drug used in preterm babies to prevent brain hemorrhage or to help close off PDA (patent ductus arteriosus - when a channel between the lungs and heart does not close off after birth as it should). Indomethacin often causes fluid retention and reduced flow of urine, which can sometimes cause deterioration in kidney (renal) function. The drug dopamine is sometimes used along with indomethacin to try and prevent negative impact on the kidneys. The review found there is not enough evidence from trials to show there is any value in giving dopamine to babies being treated with indomethacin.



  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要





主要目標:確定多巴胺是否可預防早產兒使用indomethacin治療時引起的腎功能惡化,以及沒有造成嚴重的副作用。 次要目標:評估多巴胺在兩組變異組的作用:(1)患者給予indomethacin作為預防腦室內出血,(2)患者給予indomethacin作為治療動脈導管閉鎖不全。


採用Cochrane Neonatal Review Group的標準方法(CNRG)。搜尋Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3, 2009)、MEDLINE (1966 to 2009)、EMBASE (1974 to 2009)及CINAHL (2001 to 2009) 。此外若有需要,作者則與主要的研究員聯繫以確認所需資料。




採用Cochrane Neonatal Review Group的標準方法。統計的內容包括:出院前的死亡率 三級或四級的腦室內出血 囊性腦室周圍白質軟化症腎功能衰竭(貧尿,界定為尿量少於1毫升/公斤/小時或肌酐酸40 微克分子/升 以上) 需要外科手術的動脈導管閉鎖不全。對於分類性的結果數據,作者使用相對風險和風險差異做計算評估。對於連續性的結果數據採用weighted mean difference分析。綜合資料分析假定為Fixed effect models。


有三項研究(隨機患者總數:75位)是符合這篇回顧的加入標準,三項都是單一中心的實驗,全數是新生兒加護中心接受indomethacin治療有症狀的存開性動脈導管的病人。只有部分或幾乎沒有報告證實多巴胺對某些主要結果的影響,包括出院前死亡,嚴重腦室內出血,囊性腦室周圍白質軟化或腎功能衰竭。調查的結果,對多巴胺在腦灌注或心輸出量,胃腸併發症,或內分泌毒性的影響 ,都有不足。多巴胺可改善尿排出量[WMD 0.68 毫升/公斤/小時(95 % CI為0.22 , 1.44)],但沒有任何影響血肌酐的證據(WMD 2.04 微克分子/升,CI −17.90 , 21.97)或發生乏尿(尿量<1毫升/公斤/小時) (RR 0.73 ,CI 0.35 , 1.54) 。目前還沒有任何證據顯示多巴胺對關閉失敗的動脈導管頻率的影響(RR 1.11 ,CI 0.56 , 2.19) 。





此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。


比較多巴胺(dopamine)的使用與否,對於預防早產兒因使用indomethacin所引起的腎功能不全:多巴胺並沒有被證明有助於預防indomethacin對早產兒腎臟的不利影響。Indomethacin常被用在早產兒身上,以防止腦出血或促進動脈導管的關閉(開放性動脈導管—是一條介於肺部和心臟之間在出生後應關閉而未關閉的通道)。Indomethacin經常引起液體瀦留,並減少尿流量,偶有造成腎功能惡化。因此多巴胺有時候與indomethacin 並用,以防止腎臟產生不良影響。本回顧發現,仍沒有足夠的證據顯示,給予多巴胺在以indomethacin治療的嬰兒身上有任何的價值。